5 0 • S U P P L E M E N T T O O U T PA T I E N T S U R G E R Y M A G A Z I N E • J U N E 2 0 1 6
SPECIAL ADVERTISING SECTION
Xodus Medical, Inc. - Surgical BackPacks
Xodus Medical, the leader in making surgery safer, intro-
duces Surgical BackPacks
™
— a full complement of posi-
tioning products for spinal, orthopedic, and neurological
procedures. Key components feature a protective layer of
DermaProx
™
, a specially designed material that safeguards
skin and sensitive tissue against shearing and pressure-
related complications.
Surgical BackPacks are pre-configured to fit most tables.
This innovative line of patient positioning kits can help your
healthcare facility avoid preventable injuries and CMS
Never Events, while maximizing patient safety and minimiz-
ing non-reimbursed care costs.
For more information call (800) 963-8776
or visit www.xodusmedical.com
7
DepuySynthes Advantage Program
When it comes to Outpatient Solutions, our aim is your Triple Aim.
By leveraging across our unique portfolio of products and solutions, you can enhance the Triple Aim performance
of your ambulatory surgical center (ASC) (Improve Outcomes, Greater Patient Satisfaction, Reduce Total Costs).
And when it comes to Total Joint Reconstruction in the ASC, we are developing materials and providing educa-
tional opportunities to help you build a successful outpatient strategy.
For more information, visit www.depuysynthes.com
9
Omeros, Maker of Omidria
Omeros is a Seattle-based biopharmaceutical com-
pany committed to discovering, developing, and
commercializing small-molecule and protein thera-
peutics targeting inflammation, coagulopathies, and
CNS disorders for large-market as well as orphan
indications. Its first FDA-approved product is
Omidria
®
(phenylephrine and ketorolac injection)
1%/0.3% for use during lens replacement surgery.
The company has five clinical-stage programs
focused on complement-related thrombotic
microangiopathies including atypical hemolytic
uremic syndrome; complement-related glomeru-
lopathies; Huntington's disease; addictive/ compul-
sive disorders, and urologic procedures. Omeros
also is advancing diverse preclinical programs,
including a GPCR-focused drug-development plat-
form that already has unlocked
an unprecedented number of orphan GPCR drug
targets and a novel antibody-
generating platform.
For more information call (206) 676-5000
or visit www.omeros.com
8
8
7
9
